Liraglutide/Cyanocobalamin 15mg/0.5mg/ml, 6ml (TM)

Liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA initially approved Victoza®, a 1.8 mg daily subcutaneous injection of liraglutide, in 2010 as an additional therapy to diet and exercise for the management of type 2 diabetes.